Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Trial Access Program for SHP611 in Metachromatic Leukodystrophy (Japan)
jRCT2041250146Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of cebsulfase alfa in metachromatic leukodystrophy (MLD), sponsored by Takeda. Started Jan 2026; status: active, not recruiting.
02
Drugs
cebsulfase alfa
03
Conditions
metachromatic leukodystrophy (MLD)
Beyond the preview
Go deeper on jRCT2041250146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250146.